Neola Medical AB (NEOLA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neola Medical AB (NEOLA) has a cash flow conversion efficiency ratio of -0.025x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.48 Million ≈ $-267.32K USD) by net assets (Skr97.59 Million ≈ $10.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Neola Medical AB stock valuation for the company's overall valuation and market capitalisation.
Neola Medical AB - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Neola Medical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Neola Medical AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neola Medical AB ranked by their cash flow conversion efficiency. See Neola Medical AB cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NGX Ltd
AU:NGX
|
-0.125x |
|
XTL Biopharmaceuticals Ltd
TA:XTLB
|
-0.055x |
|
Sepatu Bata Tbk
JK:BATA
|
-0.374x |
|
NETCLASS TECHNOLOGY INC Class A Ordinary Shares
NASDAQ:NTCL
|
-0.535x |
|
Manchester and London Investment Trust plc
LSE:MNL
|
-0.011x |
|
Pearl Gull Iron Ltd
AU:PLG
|
-0.128x |
|
Good Shroom Co Inc
V:MUSH
|
-0.642x |
|
Kokoh Inti Arebama Tbk
JK:KOIN
|
0.395x |
Annual Cash Flow Conversion Efficiency for Neola Medical AB (2018–2025)
The table below shows the annual cash flow conversion efficiency of Neola Medical AB from 2018 to 2025. View current stock price of Neola Medical AB for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr75.80 Million ≈ $8.16 Million |
Skr-11.95 Million ≈ $-1.29 Million |
-0.158x | -0.34% |
| 2024-12-31 | Skr68.96 Million ≈ $7.42 Million |
Skr-10.84 Million ≈ $-1.17 Million |
-0.157x | -89.83% |
| 2023-12-31 | Skr79.03 Million ≈ $8.50 Million |
Skr-6.54 Million ≈ $-704.02K |
-0.083x | +34.25% |
| 2022-12-31 | Skr67.48 Million ≈ $7.26 Million |
Skr-8.50 Million ≈ $-914.41K |
-0.126x | +26.18% |
| 2021-12-31 | Skr40.63 Million ≈ $4.37 Million |
Skr-6.93 Million ≈ $-745.89K |
-0.171x | +33.89% |
| 2020-12-31 | Skr23.55 Million ≈ $2.53 Million |
Skr-6.08 Million ≈ $-653.77K |
-0.258x | -33.84% |
| 2019-12-31 | Skr10.72 Million ≈ $1.15 Million |
Skr-2.07 Million ≈ $-222.44K |
-0.193x | -94.79% |
| 2018-12-31 | Skr13.33 Million ≈ $1.43 Million |
Skr-1.32 Million ≈ $-141.95K |
-0.099x | -- |
About Neola Medical AB
Neola Medical AB (publ), together with its subsidiary, Neola Medical, Inc., develops medical technology devices for non-invasive continuous monitoring of the lungs of preterm born infants in Sweden. It offers NEOLA, a neonatal intensive care medical device that enables continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume chan… Read more